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Background: Our goal is to develop a vascular targeting treatment for brain arteriovenous 24 
malformations (AVMs). Externalized phosphatidylserine has been established as a potential 25 
biomarker on the endothelium of irradiated AVM blood vessels. We hypothesize that 26 
phosphatidylserine could be selectively targeted after AVM radiosurgery with a ligand-directed 27 
vascular targeting agent to achieve localized thrombosis and rapid occlusion of pathological AVM 28 
vessels. 29 
Objective: The study aim was to establish an in vitro parallel-plate flow chamber to test the efficacy 30 
of a pro-thrombotic conjugate targeting phosphatidylserine.  31 
Methods: Conjugate was prepared by Lys-Lys cross-linking of thrombin with the 32 
phosphatidylserine-targeting ligand, annexin V. Cerebral microvascular endothelial cells were 33 
irradiated (5, 15, and 25 Gy) and after 1 or 3 days assembled in a parallel-plate flow chamber 34 
containing whole human blood and conjugate (1.25 or 2.5 µg/mL). Confocal microscopy was used 35 
to assess thrombus formation after flow via binding and aggregation of fluorescently-labelled 36 
platelets and fibrinogen.  37 
Results and conclusions: The annexin V-thrombin conjugate induced rapid thrombosis (fibrin 38 
deposition) on irradiated endothelial cells under shear stress in the parallel-plate flow device. 39 
Unconjugated, non-targeting thrombin did not induce fibrin deposition.  A synergistic interaction 40 
between radiation and conjugate dose was observed. Thrombosis was greatest at the highest 41 
combined doses of radiation (25 Gy) and conjugate (2.5 µg/mL). The parallel-plate flow system 42 
provides a rapid method to pre-test pro-thrombotic vascular targeting agents. These findings 43 




Brain arteriovenous malformations (AVMs) result from abnormal vascular development resulting 46 
in direct arterial-to-venous connections without intervening capillaries, forming tangled 47 
collections of vessels called the ‘nidus’. This causes high pressure arterial blood to flow directly 48 
to veins increasing the risk of vessel rupture [1]. Hemorrhage can lead to significant neurological 49 
morbidity or mortality [2, 3]. Current treatment approaches include surgical resection [4], 50 
endovascular embolization  [5] and radiosurgery [6] with the goal to achieve complete AVM vessel 51 
removal or occlusion, and prevent hemorrhage. Depending on size and location of the lesion, over 52 
90% of large AVMs are not treated safely using current treatments [7]. Hence there is a need to 53 
develop a new treatment approach to achieve complete obliteration. This could be made possible 54 
using a vascular-targeting approach by inducing rapid thrombosis precisely on targeted AVM 55 
vessels without affecting surrounding normal vessels. 56 
In vascular targeting, a target molecule is recognized on the surface of the endothelium and a ligand 57 
or antibody to the target is bound to a drug or effector of interest [8]. The concept was initially 58 
developed for the treatment of cancer, where the inherent difference between normal and tumor 59 
vessels is utilized to direct therapeutic agents selectively to the abnormal tumor endothelium [9]. 60 
To date, no valid targets have been found on the AVM endothelial surface that make it significantly 61 
different from normal vessels. Hence, we aim to use radiosurgery to prime the AVM endothelium 62 
to induce potential targets. Our previous studies demonstrated that radiation can induce up-63 
regulation of surface biomarkers on the AVM endothelium thus discriminating it from normal 64 
vessels [10-14]. These proteins may serve as potential targets for ligand-directed pro-thrombotic 65 
conjugates, enhancing the thrombotic response when induced with radiation. Our overall aim is to 66 
develop pro-thrombotic conjugates that target these radiation-stimulated proteins. However, it is 67 
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not economical to test multiple combinations of target molecules with thrombotic agents using an 68 
animal model. Hence we are developing an in vitro parallel-plate flow chamber model to simulate 69 
in vivo fluid shear stresses which rapidly tests the potency of conjugate-driven thrombus formation 70 
on irradiated endothelial cells when exposed to dynamic fluid flow [15]. Parallel-plate flow 71 
perfusion devices are widely used to evaluate platelet function, endothelial cell function, and 72 
thrombus formation [16-19].  73 
In this study, we aimed to investigate the pro-thrombotic efficacy of a phosphatidylserine (PS)-74 
targeting annexin V-thrombin conjugate in irradiated human microvascular endothelial cells using 75 
the parallel-plate flow system. PS is a negatively charged phospholipid present in the membrane 76 
of all cells. It normally localizes to the inner membrane leaflet that faces the cytosol, but under 77 
certain conditions will translocate to the outer leaflet of the plasma membrane where it plays a role 78 
in various cellular processes [20, 21]. PS plays a vital role during apoptosis where it is exposed on 79 
the surface of apoptotic cells to trigger phagocytosis [22]. PS externalization has been shown to 80 
occur on tumor endothelium, allowing it to be exploited for imaging and vascular targeting using 81 
PS-directed antibodies and immunoconjugates [23-25]. In addition, radiation therapy has been 82 
reported to enhance PS exposure on tumor endothelium, serving as a potential radiation-stimulated 83 
target in future clinical applications [25, 26]. Our recent studies also demonstrated significant 84 
externalization of endothelial PS upon radiation both in vitro, in brain microvascular endothelial 85 
cells, and in vivo, using a rat model of AVM [11, 12]. This suggests PS could be used as a vascular 86 
target in irradiated AVMs. 87 
In the current study, we investigated the efficacy of a PS-targeting annexin V-thrombin conjugate 88 
at inducing thrombus formation under parallel-plate flow on irradiated human brain microvascular 89 
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endothelial cells. Using whole human blood perfusion, we investigated the effect of conjugate 90 
dose, radiation dose and methods of thrombus analysis, in this system. 91 
Materials and methods 92 
Annexin V-thrombin conjugate preparation 93 
Thrombin (Jomar Life Research) was conjugated with annexin V (Jomar Life Research) using a 94 
Lys-Lys protein-protein conjugation kit (Click Chemistry Tools Bioconjugate Technology 95 
Company) according to the manufacturer’s instructions. Briefly, 300 µL thrombin (2 mg/mL) in 96 
BupH buffer (pH 7.5) was labelled using 12-fold molar excess tetrazine (Tz) reagent, and 300 µL 97 
annexin (1 mg/mL) in BupH buffer was labelled using 12-fold molar excess trans-cyclooctene 98 
(TCO) reagent. Annexin-TCO and thrombin-Tz were mixed together (ratio 1:2) and the 99 
conjugation reaction analyzed by SDS-PAGE (Supplementary Fig S1). Image J (Version 1.5, 100 
Rasband, W.S., ImageJ, National Institute of health, USA) was used to determine efficiency of 101 
conjugation as 40%. Thrombin activity was also measured before and after conjugation using a 102 
commercially available thrombin activity assay kit (Ana Spec, CA, USA).  103 
Blood collection 104 
All experimental procedures using human blood were approved by the Macquarie University 105 
Human Ethics Committee (approval number HREC: 5201300883) and were carried out following 106 
the Australian Code of Practice for the Care and Use of Human tissues for Scientific Purposes 107 
(version 4) with informed consent. Fresh human whole blood was collected by venepuncture in a 108 
sodium citrate tube (BD Bioscience) from healthy volunteers. Blood was kept at room temperature 109 
while 3 µg/mL rhodamine 6G (Sigma-Aldrich) was added to label the platelets and 1.3 mg/mL 110 
Fibrinogen-FITC was added to monitor thrombus formation.  The fibrinogen from human plasma 111 
(Sigma-Aldrich) was commercially purchased and conjugated to FITC using the FluoroTagTM 112 
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FITC Conjugation Kit (Sigma-Aldrich) according to the manufacturer’s instructions. The blood 113 
was then re-calcified with 10 mM calcium chloride and 5 mM magnesium chloride immediately 114 
prior to use in the parallel-plate flow system. 115 
Cell culture and irradiation 116 
HCMEC/D3 (CELLutions Biosystems Inc), an immortalized cell line from cerebral microvascular 117 
endothelial cells, were routinely cultured in EBM-2 endothelial basal medium (Lonza) 118 
supplemented with 5% fetal bovine serum, 1% Penicillin/Streptomycin, 10 mM HEPES (Life 119 
Technologies), and 1 ng/mL human basic fibroblast growth factor (Sigma-Aldrich) at 37˚C in 5% 120 
carbon dioxide and passaged at 90% confluence with trypsin-EDTA. All culture vessels were pre-121 
coated with 100 µg/mL rat tail collagen (In Vitro Technologies).  122 
For irradiation, cells were seeded at 1x104 cells/mL onto collagen-coated 35 mm glass bottom petri 123 
dishes (MatTek Corporation) containing 1.5 mL EBM-2 medium and allowed to grow for 2 days 124 
to achieve 100% confluency. Cells were treated with a single dose of 5, 15 or 25 Gy of ionizing 125 
radiation by linear accelerator (LINAC; Elekta Synergy, Crawley, UK) at Macquarie University 126 
Hospital (Sydney, Australia), as previously described [11, 13]. Non-irradiated cells treated 127 
identically but without radiation (sham) were used as controls. At 1, 3 or 5 days after radiation or 128 
sham treatment, the cells were transferred to the parallel-plate flow chamber. 129 
Parallel-plate flow chamber assembly and operation 130 
The flow apparatus used in this study is the parallel-plate flow chamber (Glycotech Co., 131 
Gaithersburg, ML) encompassing an enclosed circulation system consisting of: 1) flow deck with 132 
inlet and outlet port connected to tubing; 2) silicon rubber gasket with a flow width of 1 cm and a 133 
thickness of 0.010 cm fitted beneath the deck; 3) 35 mm glass-bottom petri dish which contained 134 
the cultured cells. A vacuum port was used to seal the dish with gasket to the petri dish containing 135 
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100% confluent HCMEC/D3 cells which was then connected to the pulsatile syringe pump using 136 
silicone tubing filled with whole blood. To optimize flow conditions, the pump was allowed to run 137 
with the confluent cells in EBM-2 medium rather than blood with variations in flow rate (20 138 
strokes/min, 38 strokes/min, 52 strokes/min, or 66 strokes/min), volume (1.4 mL/min, 2.4 mL/min, 139 
3.4 mL/min or 4.4 mL/min) and flow time (5 min, 10 min, 15 min, or 20 min) where stability, 140 
behavior, and confluency of the cells were observed after each experiment using brightfield 141 
microscopy.                                                                                         142 
Average wall shear stress determination 143 
To determine the average wall shear stress within the flow chamber, 6 µm fluorescent beads 144 
(FluoroSpheres sulphate microspheres, Molecular Probes, Ore, USA) were introduced in a non-145 
cellularized circulatory system at a volume of 20 µL (500x dilution) and images were captured at 146 
100 ms frame intervals with 10 ms exposure time where the peak speed of the beads in the center 147 
line of the flow chamber was determined over the duration of the pump cycle. The wall shear stress 148 
(WSS, in dynes/cm2) can be related to the peak (center line) velocity (VPeak in m/s) by: WSS = 10 149 
 (4VPeak/t), where µ is viscosity of water (8.90 x 10
-4) in Pascal seconds (Pa.s) which is 10 times 150 
less compared to blood viscosity, and t is the chamber thickness in meters.    151 
Thrombosis under flow  152 
The pump was filled with 12 mL of the labelled whole human blood and assembled with the petri 153 
dish containing sham or irradiated cells. At time zero, different concentrations of conjugate were 154 
injected into the system to achieve final concentrations of 1.25 µg/mL, 2.5 µg/mL or, 5 µg/mL. 155 
The pump was operated under optimized flow conditions (described in results). After 15 min, the 156 
pump was stopped, the unit was disassembled, and the cells washed three times with phosphate-157 
buffered saline followed by fixation with 50% ethanol for 15 min at room temperature. The cells 158 
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were stained with 100 µg/mL Hoechst 33342 solution (Thermo-Fisher Scientific), washed, and 159 
mounted for confocal microscopic analysis.  Experiments were also carried out with free 160 
unconjugated 1.5 µg/mL thrombin and free unconjugated 0.9 µg/mL annexin V as control, where 161 
percent loss of thrombin activity (5%) was taken into consideration. An equivalent volume of 162 
saline injected into the system was used as a non-conjugate control. 163 
Microscopy and image analysis 164 
Cells were viewed under bright-field and using ex358nm/em461nm channels for Hoechst. Platelets 165 
and fibrin were viewed at ex550nm/em570nm and ex495/em519nm respectively. Z stacks were 166 
taken and 3D image reconstruction was done using Bitplane (IMARIS software version 8) for 167 
measuring thrombus volume. First, the image was selected by adding its surface into the analysis 168 
toolbar and absolute intensity was applied after selecting the source channel. Threshold was 169 
applied and adjusted manually until the image distribution over the surface was observed with all 170 
deposited fibrin. The volume was obtained by unifying whole fibrin volume in a field of view. 2D 171 
analysis of platelet area was obtained with the same software tool settings. Five fields of view from 172 
each experiment were selected and the average measurements were considered for analysis. Data 173 
analysis was performed using Prism 6.01 (Graphpad software Inc., La Jolla CA). Values are given 174 
as mean ± standard deviation (SD) of 3 independent experiments. Multiple comparisons were 175 
performed using two-way ANOVA with Tukey’s post-hoc analysis and the level of significance 176 
was set at p<0.05. 177 
Analysis of fibrin degradation product (FDP) 178 
As a further measure of thrombotic activity in the flow system, whole blood was analyzed after 179 
flow for the presence of fibrin degradation product (FDP). Whole blood was collected after each 180 
flow experiment, centrifuged at 1000 x g for 10 min to separate plasma which was stored at -80˚C 181 
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until analysis using a fibrin degradation product (FDP) enzyme-linked immunosorbent assay 182 
(ELISA) kit (Jomar Life Research) according to the manufacturer’s instructions. 183 
Results  184 
Average flow rate and shear stress 185 
Flow conditions were optimized to ensure that cells remained adherent to the surface until the end 186 
of the experiment. The stroke rate was optimized at 38 strokes/min. The flow volume and flow 187 
time were found to be optimal at 2.4 mL/min and 15 min respectively (Supplementary Fig S2A, 188 
B, C). The average wall shear stress using these parameters was calculated based on bead velocity 189 
over time and measured as 3.1 dynes/cm2. Increasing any of these parameters led to decreased cell 190 
confluency. The shear stress profile confirmed the pulsatile flow of the system simulating the in 191 
vivo environment (Supplementary Fig S2D). 192 
Effect of radiation on HCMEC/D3 cell confluency 193 
Cell confluency after 15 min of flow at optimized conditions was monitored over a period of 5 194 
days post radiation (Supplementary Fig S3). No decrease in cell confluency was observed at day 195 
1 and day 3 compared to the control at all radiation doses after flow. At day 5, cell loss and cellular 196 
hypertrophy were observed. The enlargement and flattening of cells is consistent with radiation-197 
induced acquisition of a senescent phenotype [27]. While the cells spread to provide greater 198 
coverage of the collagen-coated dish, confluency was still reduced, hence all subsequent 199 
experiments were performed at day 1 and 3 post-irradiation to reduce non-specific induction of 200 
thrombosis via collagen exposure.                   201 
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Annexin V-thrombin conjugate enhances platelet binding and aggregation on irradiated 202 
endothelial cells under flow 203 
Evidence for thrombus formation was determined by measuring platelet and fibrinogen 204 
aggregation and accumulation by confocal microscopy (Fig 1). We first determined platelet 205 
adhesion and aggregation on the endothelial surface, one of the first steps in thrombus formation. 206 
The average size of the platelet aggregates as well as the total area of platelet deposition per field 207 
of view was measured. Overall, increased platelet binding and aggregation was observed with 208 
increasing doses of both conjugate and radiation (Fig 2A – D). The average size of platelet 209 
aggregates (Fig 2A, B) increased significantly (2.1-fold, p<0.0001) at the higher doses of 15 and 210 
25 Gy using 2.5 µg/mL conjugate dose at both day 1 and day 3. No major differences were 211 
observed between day 1 and day 3 values. Total platelet area (per field of view) increased modestly 212 
with each radiation dose in the absence of conjugate (up to 1.5 – 2-fold), though this was not 213 
statistically significant (Fig 2C, D). However, in the presence of conjugate, significant increases 214 
in total platelet area were observed relative to the non-irradiated, saline control at all radiation 215 
doses (3 – 4-fold; Fig 2C, D).  216 
Figure 1: Platelet aggregation and fibrin formation on irradiated endothelial cells. Representative 217 
confocal images of platelet aggregation and fibrin formation on irradiated endothelial cells in the 218 
parallel-plate flow system at day 1 or day 3 post-irradiation or sham. Platelets were pre-stained in 219 
whole blood with R6G (red), and FITC-labelled fibrinogen (green) was added prior to circulation. 220 
Cell nuclei were stained post-flow with Hoechst 33342 (blue). Bar = 50 µm; magnification = 200x. 221 
Figure 2: Platelet aggregation on irradiated endothelial cells. Average size of platelet aggregates 222 
(µm2) at day 1 (A) and day 3 (B) post-irradiation. Total platelet area per field of view at day 1 (C) 223 
and day 3 (D). Data are shown as mean ± SD (3 independent experiments) and were analyzed 224 
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using two-way ANOVA with Tukey’s post-hoc analysis. ****p<0.0001, ***p<0.001, **p<0.01, 225 
*p<0.5 comparisons relative to saline, non-irradiated control. ####p<0.0001, #p<0.5, comparisons 226 
within radiation dose group. 227 
Annexin-V thrombin conjugate enhances fibrin deposition on irradiated endothelial cells under 228 
flow. 229 
Fibrin deposition is representative of a more mature and stable thrombus hence we used 230 
incorporation of fluorescently labelled fibrinogen as a measure of stable thrombus formation (Fig 231 
1 and Fig 3A – G). We used 3D reconstruction using z stacks of confocal microscopy (Fig 3A, B, 232 
C) to determine the average volume of individual fibrin thrombi (Fig 3D, E) as well as the total 233 
fibrin volume per field of view (Fig 3F, G) at day 1 and 3. At both post-irradiated time points, no 234 
fibrin deposition was observed on non-irradiated controls with or without conjugate addition (Fig 235 
1 and Fig 3D – G). No fibrin deposition was observed at any radiation dose in the absence of 236 
conjugate. A dose of 1.25 µg/mL conjugate showed significant fibrin development at 15 Gy and 237 
25 Gy with minimal to no fibrin deposition at 5 Gy on both day 1 and day 3 (Fig 3D – G). A dose 238 
of 2.5 µg/mL initiated fibrin formation at 5 Gy, followed by formation of a more interlinked fibrin 239 
network at 15 and 25 Gy. At both 15 Gy and 25 Gy using 2.5 µg/mL conjugate, average fibrin 240 
volume increased 32 – 64-fold (P<0.0001) compared to non-irradiated saline control and 241 
respective irradiated saline control (at same radiation dose) (Fig 3D, E). No major differences were 242 
noted between day 1 and day 3 except significant differences between the two conjugate doses 243 
were more apparent at day 1 (P<0.0001). Values of total fibrin volume (Fig 3F, G) showed a 244 
similar trend to average volume (Fig 3D, E).  245 
Figure 3: Fibrin thrombus formation on irradiated endothelial cells. (A) Representative confocal 246 
image of interlinked fibrin fibers in 2D (green); (B) 3D reconstruction of Z stacks showing 247 
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deposited fibrin on the surface; (C) individual 3D fibrin thrombi (yellow) could be measured 248 
independently to give average fibrin volume (D, E) or summed to give total fibrin volume per field 249 
of view (F, G) at day 1 (D, F) or day 3 (E, G). Data are shown as mean ± SD (3 independent 250 
experiments) and were analyzed using two-way ANOVA with Tukey’s post-hoc analysis. 251 
***p<0.001, **p<0.01, comparisons relative to non-irradiated control. ####p<0.0001, ##p<0.01, 252 
#p<0.5, comparisons with saline control within radiation dose group. Scale bar = 30 µm. 253 
Magnification = 200x. 254 
Free thrombin or annexin V induces low level activation of blood coagulation  255 
We also examined thrombosis in the presence of free, non-targeted thrombin and free annexin V 256 
at activity levels/doses equivalent to that of the conjugate. Base levels of platelet binding and 257 
aggregation were observed at all radiation doses using saline, free thrombin and free annexin under 258 
flow at both time points (Fig 4). Average platelet area was not generally affected by free thrombin 259 
or annexin V at any radiation dose at either time point (Fig 4A, B). Total platelet area increased 2 260 
– 3-fold in response to free thrombin in non-irradiated controls and at all radiation doses in the 261 
range relative to the non-irradiated saline control (Fig 4C, D). Similarly, annexin V increased total 262 
platelet area at the higher radiation doses relative to the non-irradiated saline control, however was 263 
not significantly different to the respective saline control at the equivalent radiation dose.  264 
Figure 4: Platelet and fibrin deposition in response to free annexin and free thrombin. Average 265 
platelet area (A, B), total platelet area (C, D), average fibrin volume (E, F), and total fibrin volume 266 
(G, H) in response to saline control, free thrombin and free annexin at each radiation dose on both 267 
day 1 (A, C, E, G) day 3 (B, D, F, H). Data are shown as mean ± SD (3 independent experiments) 268 
and were analyzed using two-way ANOVA with Tukey’s post-hoc analysis. ****p<0.0001, 269 
***p<0.001, **p<0.01, *p<0.5, comparisons relative to sham-irradiated, saline control. 270 
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####p<0.0001, ###p<0.001, ##p<0.01, #p<0.5, comparisons relative to saline control within 271 
radiation dose group. 272 
Average fibrin volume and total fibrin volume increased between 4 – 5-fold in response to 273 
thrombin alone relative to the non-irradiated saline control at both days, however, minimal 274 
significant difference was seen relative to the respective irradiated saline controls (at same dose) 275 
(Fig 4E – H). However, when compared to levels of fibrin deposition in response to conjugate, 276 
maximal levels of total fibrin deposited in response to free thrombin and free annexin V were in 277 
the range 0.05 – 0.1 x 105 µm3, while the conjugate resulted in volumes in the range of 1 – 2 x 105 278 
µm3, a 10 – 20-fold increase.  279 
Plasma FDP level 280 
The FDP concentration was measured in plasma from whole blood after flow in blood treated with 281 
2.5 µg/mL conjugate at the day 1-time point (Fig 5). Significant increases were observed at both 282 
5 Gy (28-fold, p<0.01) and 25 Gy (68-fold, p<0.0001). FDP levels increased 9-fold in response to 283 
15 Gy however this did not reach statistical significance with the 3 replicate samples. 284 
Figure 5: Plasma FDP concentration after flow. Presence of FDP analyzed in plasma treated with 285 
2.5 µg/mL conjugate at day 1 post-irradiation or sham under flow. Data are shown as mean ± SD 286 
(3 independent experiments). Statistical differences were analyzed using one-way ANOVA with 287 
Tukey’s post-hoc analysis. ****p<0.0001, **p<0.01 comparisons relative to sham-irradiated 288 





In this study, we investigated the efficacy of an annexin V-thrombin conjugate to bind selectively 292 
to irradiated endothelial cells and induce thrombosis under flow using an in vitro parallel-plate 293 
flow chamber. This demonstrated the successful development and use of an in vitro flow device 294 
to test the effect of a pro-thrombotic conjugate in stimulating platelet aggregation and fibrin 295 
formation. Here, we successfully used fresh human whole blood with irradiated endothelial cells 296 
to demonstrate in vitro shear-dependent thrombosis in the presence of a PS-targeting pro-297 
thrombotic conjugate. The current study demonstrates that durable platelet adherence to HCMEC 298 
and stable fibrin thrombi formation is possible by priming the endothelial cells with radiosurgery 299 
and using our pro-thrombotic vascular targeting agent under flow conditions.  300 
Cell irradiation causes cellular changes that tend to up-regulate various cell adhesion, pro-301 
inflammatory, and pro-thrombotic molecules on the endothelial surface [10, 14, 28, 29], and this 302 
includes the externalization of PS [24]. We reported on post-irradiation PS externalization on 303 
microvascular endothelial cells in vitro, using live cell imaging, and in vivo, using near-infrared 304 
fluorescent optical imaging in a rat AVM model [11, 12]. Thus, PS appears a valid target for a 305 
vascular targeting approach to AVM treatment and we developed a PS-targeting, annexin V-306 
thrombin conjugate for testing. In agreement with earlier studies, we have now demonstrated that 307 
this conjugate can bind effectively on irradiated endothelial cells, and further, that this occurs under 308 
high flow and initiates platelet aggregation and fibrin clots in the presence of whole blood. Not 309 
unexpectedly, higher radiation doses (15 and 25 Gy) caused significantly greater thrombus 310 
formation when compared to the lowest dose (5 Gy) and when in combination with a conjugate 311 
dose of 2.5 µg/mL. However, our data suggest that there was a significant synergistic interaction 312 
between the effects of radiation dose and conjugate dose, and that low radiation dose could still 313 
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induce endothelial PS exposure and thrombosis when used in combination with the higher 314 
conjugate concentration. This is considered noteworthy for future applications to AVM treatment 315 
in the clinic. Treatment of large AVMs by stereotactic radiosurgery alone is often limited by the 316 
high dose requirement to achieve complete obliteration (>15 Gy) [30]. This is often not achievable 317 
in large lesions without significant off-target effects to the surrounding brain. The potential ability 318 
to use a lower dose of radiation when combined with a vascular targeting agent would potentially 319 
increase the number of patients considered treatable. It was important in this study to examine not 320 
just thrombus formation but also thrombus stability in the presence of the developed conjugate. 321 
Binding and aggregation of platelets which occurs early in the clotting cascade does not necessarily 322 
indicate that a stable thrombus will be formed [33]. Formation of fibrin polymers occurs later in 323 
the coagulation cascade to attain a mature, stable clot. Thrombin causes activation of platelets 324 
allowing binding of soluble fibrinogen in the blood, which is then cleaved to insoluble fibrin by 325 
active thrombin and polymerized and cross-linked to achieve greater stability. Fluorescently 326 
labelling fibrinogen with FITC gave evidence of these later thrombotic events and clear fluorescent 327 
imagery of fibrinogen deposition and aggregation and what appeared to be the development of 328 
fibrin branching representative of growing thrombi. This technique of labelling thrombus through 329 
fibrinogen has been used previously as an advanced method of studying platelet activation in 330 
whole blood [31, 32]. Fibrinogen labelled with near-infrared fluorophores has also been used in 331 
vivo as a marker of clot formation in animal models (Ohnishi et al 2006) [33]. It must be noted 332 
however that in the current study fibrinogen deposition was used as a surrogate marker of thrombus 333 
formation. We did not specifically assess fibrinogen cleavage to fibrin by thrombin in situ and in 334 
future inclusion of post-flow immunostaining with a fibrin-specific antibody would further clarify 335 
fibrinogen to fibrin cleavage rates by the targeted thrombin. However we did observe the 336 
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progressive accumulation of what appeared a branched fibrin network characteristic of insoluble 337 
polymerized fibrils. 338 
With this assumption in mind, confocal microscopy and digital image reconstruction allowed us 339 
to reconstruct a 3D image of this networked fibrinogen deposition to give us more detailed 340 
information on whole thrombus volume using fibrin structure. Similar analysis approaches were 341 
suggested by other authors previously [19]. It was possible to observe the initiation of fibrin and 342 
branched fibrin network on activated platelets in response to increases in radiation and conjugate 343 
dose. Measuring thrombosis using the deposited fibrin was far superior to assessing platelet 344 
binding and aggregation. However, by examining both platelet and fibrin deposition in this study, 345 
we could see that though free thrombin caused platelet activation with more platelet aggregates 346 
under flow, the level of activation was still well below the baseline activation of combined 347 
conjugate and radiation dose groups. In addition, there was no significant fibrin formation 348 
observed in response to thrombin alone, in comparison to that induced by conjugate. Radiation 349 
alone (in the absence of conjugate), caused a dose-dependent increase in platelet adhesion and 350 
aggregation, however did not significantly increase fibrin deposition. Similarly, conjugate had a 351 
dose-dependent effect on platelet aggregation but not fibrin deposition in the absence of radiation. 352 
Thus, in alignment with the literature [14, 34], radiation appears to induce a pro-thrombotic, 353 
platelet-binding surface on the endothelium but does not necessarily induce rapid formation of 354 
more stable thrombi. All thrombus formation is a balance between the activities of pro- and anti-355 
coagulant factors present on the endothelial surface and in the plasma. The normal, healthy 356 
endothelium provides an anti-coagulant milieu which our approach utilizes to prevent off-target 357 
activation of thrombin on normal vessels. However on the irradiated endothelium, proclivity 358 
toward a pro-coagulant state tips the balance toward coagulation through down-regulation of 359 
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molecules such as thrombomodulin and subsequent limitation of protein C activation which 360 
normally acts to restrain the coagulation cascade (Wang 2007; Wang 2002). Our results show that 361 
this alone may not be enough to reproducibly overcome the inherent thromboresistance of the 362 
endothelium, however, together with delivery of excess, targeted thrombin saturates the irradiated 363 
region, tipping the balance toward a pro-coagulative state. Here we show that delivery of PS-364 
targeted thrombin to the irradiated cells is far superior to adding free thrombin in the blood. This 365 
further suggests that systemic thrombosis would be unlikely to occur in the presence of conjugate 366 
on non-irradiated vessels without the initial pro-thrombotic radiation stimulus. Further in vivo 367 
studies will be required to assess long term thrombus stability and specificity. 368 
In addition, we used FDP analysis of the unconditioned (post-flow) plasma to assess thrombus 369 
stability since a fine balance between clot formation and fibrinolysis determines the thrombus 370 
maturity [35]. The determination of FDP in plasma or serum has been used previously and 371 
considered as an effective predictor showing patient’s coagulative-fibrinolytic state in thrombosis, 372 
acute myocardial infarction, or sepsis [36] . Our findings clearly indicate the presence of increasing 373 
levels of FDP in response to radiation at the 2.5 µg/mL conjugate dose which confirmed the fibrin 374 
deposition data and formation of highly stable thrombus under flow conditions. This suggests the 375 
possibility of achieving fully developed thrombosis even at low radiation doses. 376 
The development of this parallel-flow system has significant advantages over prior studies. The 377 
inclusion of 3 different methods for analysis of thrombus formation was important to fully 378 
determine the effects of combined conjugate and radiation doses and for their comparison to the 379 
effects of thrombin alone. The pulsatile nature of the pump further added advantage to this study 380 
by simulating the in vivo hemodynamic condition using its pulsatile flow pattern. However, the 381 
system is limited with respect to achieving a completely physiological flow rate and shear stress 382 
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level, which was limited by the ability of the endothelial cells to adhere to the artificial collagen 383 
substratum. Average WSS measurements lie in the range of 2 – 67.4 dynes/cm2 for the large 384 
cerebral feeder vessels of AVMs [37], and in the range of 7 - 23 dynes/cm2 for normal intracranial 385 
vessels [38]. The ability to culture human AVM endothelial cells isolated from surgically excised 386 
human AVMs would also be more physiologically relevant but we consider not necessary for early 387 
development and pre-testing of conjugate once a valid target is identified.  388 
These preliminary investigations in the flow system naturally require further validation in vivo. 389 
Future testing of the PS-targeting conjugate at similar dose combinations in our AVM animal 390 
model will allow assessment of thrombus formation in appropriately sized vessels under deranged 391 
hemodynamic conditions that reflect those in human AVMs (Raoufi Rad 2017, Tu et al 2010). 392 
This will not only advance the approach toward translation once target expression is validated 393 
using imaging in AVM patients after irradiation, but will validate the utility of the established 394 
parallel-plate flow system for pre-assessment of other ligand-guided pro-thrombotic agents 395 
targeting other putative radiation-stimulated targets. 396 
Conclusions 397 
Our findings demonstrate the first evidence of stable thrombus formation on irradiated endothelial 398 
cells in a parallel-flow device by designing and testing a pro-thrombotic conjugate targeting PS. 399 
Using this system, we established dose combinations of conjugate and radiation that could 400 
effectively induce highly stable thrombus formation in the presence of whole blood that can now 401 
be applied in a pre-clinical animal study. Further, development of this system also enables us to 402 
rapidly screen other potential target molecules and pro-thrombotic conjugates in future, prior to 403 
testing in pre-clinical models. Improving the treatment potential of stereotactic radiosurgery in 404 
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AVM therapy by combining with ligand-directed vascular targeting remains a viable objective 405 
with PS a potential target.         406 
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